Download PDF
Zeitschrift für Komplementärmedizin 2021; 13(02): 50-53
DOI: 10.1055/a-1410-1576
Wissen
Heilpflanze

Mariendistel – Arzneipflanze des Jahres 2021 in Österreich

Sigrun Chrubasik-Hausmann∗
› Further Information
    Permissions and Reprints

Summary

Obwohl schon im Mittelalter bei Lebererkrankungen genutzt, ist die klinische Wirksamkeit immer noch nicht zweifelsfrei belegt – auch nicht für andere vielversprechende Indikationen

Keywords

Heilpflanze - Mariendistel - Silybummarianum L. - Heilpflanzenporträt


Publication History

Article published online:
21 April 2021

© 2021. Thieme. All rights reserved.

© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co.
KG

 

  • Literatur

  • 1 Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 2018; 32: 2202-2213
    CrossrefPubMedGoogle Scholar
  • 2 Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.) – Chemistry, bioavailability, and metabolism. Molecules 2017; 22: 1942
    CrossrefPubMedGoogle Scholar
  • 3 Blaschek W, Hilgenfeldt U, Holzgrabe U, Reichling J, Ruth P, Schulz V. Hagers Enzyklopädie der Arzneistoffe und Drogen. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2016. Cardui mariae fructus
    Google Scholar
  • 4 Camini FC, Costa DC. Silymarin: not just another antioxidant. J Basic Clin Physiol Pharmacol 2020; 31: 4
    CrossrefPubMedGoogle Scholar
  • 5 Da Silva TF, Ferraz AC, Almeida LT, Caetano CCDS, Camini FC, Lima RLS, Andrade ACDSP, de Oliveira DB, Rocha KLS, Silva BM, de Magalhães JC, Magalhães CLB. Antiviral effect of silymarin against Zika virus in vitro. Acta Trop 2020; 211: 105613
    CrossrefPubMedGoogle Scholar
  • 6 De Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis. World J Gastroenterol 2017; 23: 5004-5017
    CrossrefPubMedGoogle Scholar
  • 7 Delmas D, Xiao J, Vejux A, Aires V. Silymarin and cancer: A dual strategy in both in chemoprevention and chemosensitivity. Molecules 2020; 25: 2009
    CrossrefPubMedGoogle Scholar
  • 8 Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: The state of the art. Molecules 2019; 24: 2155
    CrossrefPubMedGoogle Scholar
  • 9 Elhag R, Mazzio EA, Soliman KF. The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines. Anticancer Res 2015; 35: 1263-1269
    Google Scholar
  • 10 Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phytother Res 2019; 33: 862-870
    CrossrefPubMedGoogle Scholar
  • 11 Gándara L, Sandes E, Di Venosa G, Prack Mc Cormick B, Rodriguez L, Mamone L, Batlle 1 A, Eiján AM, Casas A. The natural flavonoid silybin improves the response to photodynamic therapy of bladder cancer cells. J Photochem Photobiol B 2014; 133: 55-64
    CrossrefPubMedGoogle Scholar
  • 12 Haddadi R, Shahidi Z, Eyvari-Brooshghalan S. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms. Phytomedicine 2020; 79: 153320
    CrossrefPubMedGoogle Scholar
  • 13 Hadi A, Pourmasoumi M, Mohammadi H, Symonds M, Miraghajani M. The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Complement Ther Med 2018; 41: 311-319
    CrossrefPubMedGoogle Scholar
  • 14 Kalopitas G, Antza C, Doundoulakis I, Siargkas A, Kouroumalis E, Germanidis G, Samara M, Chourdakis M. Impact of silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis. Nutrition 2021; 83: 111092
    CrossrefPubMedGoogle Scholar
  • 15 Liu CH, Jassey A, Hsu HY, Lin LT. Antiviral activities of silymarin and derivatives. Molecules 2019; 24: 1552
    CrossrefPubMedGoogle Scholar
  • 16 Mastron JK, Siveen KS, Sethi G, Bishayee A. Silymarin and hepatocellular carcinoma: A systematic, comprehensive, and critical review. Anticancer Drugs 2015; 26: 475-486
    CrossrefPubMedGoogle Scholar
  • 17 Meng Q, Liu K. Pharmacokinetic interactions between herbal medicines and prescribed drugs: Focus on drug metabolic enzymes and transporters. Curr Drug Metab 2014; 15: 791-807
    CrossrefPubMedGoogle Scholar
  • 18 Moayedi Esfahani BA, Reisi N, Mirmoghtadaei M. Evaluating the safety and efficacy of silymarin in β-Thalassemia patients: A review. Hemoglobin 2015; 39: 75-80
    CrossrefPubMedGoogle Scholar
  • 19 Mohammadi H, Hadi A, Arab A, Moradi S, Rouhani MH. Effects of silymarin supplementation on blood lipids: A systematic review and meta-analysis of clinical trials. Phytother Res 2019; 33: 871-880
    CrossrefPubMedGoogle Scholar
  • 20 Mohd Fozi NF, Mazlan M, Shuid AN, Isa Naina M. Milk thistle: A future potential anti-osteoporotic and fracture healing agent. Curr Drug Targets 2013; 14: 1659-1666
    CrossrefPubMedGoogle Scholar
  • 21 N.N. Silybi Mariani Fructus. In ESCOP Monographs. 2nd Edition. Supplement 2009 Stuttgart: Thieme; 2009: 222-248
  • 22 N.N. Assessment report on Silybum marianum (L.) Gaertn., fructus. 2013. Im Internet https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-silybum-marianum-l-gaertn-fructus_en.pdf
  • 23 N.N. European Union herbal monograph on Silybum marianum(L.) Gaertn., fructus. 2018. Im Internet https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-silybum-marianum-l-gaertn-fructus_en.pdf
  • 24 Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008; 15: 9-20
    CrossrefPubMedGoogle Scholar
  • 25 Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Tsai WY, Wu DP, Lee V, Greenlee H. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther 2014; 13: 46-53
    CrossrefPubMedGoogle Scholar
  • 26 Soleimani V, Delghandi PS, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytother Res 2019; 33: 1627-1638
    CrossrefPubMedGoogle Scholar
  • 27 Stolf AM, Cardoso CC, Acco A. Effects of silymarin on diabetes mellitus complications: A review. Phytother Res 2017; 31: 366-374
    CrossrefPubMedGoogle Scholar
  • 28 Tao L, Qu X, Zhang Y, Song Y, Zhang SX. Prophylactic therapy of silymarin (milk thistle) on antituberculosis drug-induced liver injury: A meta-analysis of randomized controlled trials. Can J Gastroenterol Hepatol 2019; 2019: 3192351
    PubMedGoogle Scholar
  • 29 Xiao F, Gao F, Zhou S, Wang L. The therapeutic effects of silymarin for patients with glucose/lipid metabolic dysfunction: A meta-analysis. Medicine (Baltimore) 2020; 99: e22249
    CrossrefPubMedGoogle Scholar
  • 30 Yang Z Zhuang 2, Lu Y, Xu Q, Chen X. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int 2014; 2014: 941085
    CrossrefPubMedGoogle Scholar
  • 31 Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H, Niu J. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials. Medicine (Baltimore) 2017; 96: e9061
    CrossrefPubMedGoogle Scholar